Sofinnova Partners

Sofinnova Partners invests in start-ups, early-stage companies, corporate spin-offs and occasionally restarts. Our focus is on life sciences. We proactively source deals, take a lead role, we are most often the first institutional investor in Round A financings, and we lead our portfolio companies until exit. We sit on the boards of our portfolio companies and play an active role as from the formation phase alongside our entrepreneurs. Sofinnova invests throughout Europe from our headquarters in Paris with a portion of our investments made in the rest of the world.

HQParis, FR
Cybersecurity ratingAMore
Sofinnova Partners was founded in 1972 and is headquartered in Paris, FR

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Sofinnova Partners

Rafaèle Tordjman

Rafaèle Tordjman

Managing Partner
Denis Lucquin

Denis Lucquin

Managing Partner
Graziano Seghezzi

Graziano Seghezzi

Managing Partner, Partner
Antoine Papiernik

Antoine Papiernik

Monique Saulnier

Monique Saulnier

Managing Partner & CFO
Henrijette Richter

Henrijette Richter

Show more

Sofinnova Partners Office Locations

Sofinnova Partners has an office in Paris
Paris, FR (HQ)
7 Boulevard Haussmann
Show all (1)

Sofinnova Partners Investment Portfolio

Stage Distribution


Top Sectors Distribution


Round Size Distribution


Sofinnova Partners News and Updates

Sofinnova Partners leads Series A round for DMC

DMC, an early-stage biotech company, has secured an undisclosed amount of Series A funding. Sofinnova Partners led the round.

Sofinnova Partners recruits Bhaman as partner

Sofinnova Partners, a European life sciences venture firm, has appointed Maina Bhaman as a partner. Previously, she worked at Touchstone Innovations where she was director of healthcare investment.

Sofinnova Partners appoints Seghezzi as managing partner

Sofinnova Partners has named Graziano Seghezzi as a managing partner. Seghezzi first joined the venture firm in 2001.

Sofinnova Partners Online and Social Media Presence

Embed Graph

Sofinnova Partners Blogs

Redx Pharma plc Placing to raise c.£25.5 million and Open Offer to raise up to £2.2 million and Conversion of loan notes

Alderley Park, 2 December 2020 - Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces today that it has conditionally raised c.£25.5 million (before expenses) by way of a placing of 45,603,575 new Ordinary Shares (t…

Catamaran Bio Launches with $42 Million Financing to Develop Off‑the‑Shelf CAR-NK Cell Therapies to Treat Solid Tumors

Company brings together scientific founders with leading-edge expertise in NK cells and leadership team with deep cell therapy experience   Proceeds to advance two lead CAR-NK cell therapy programs based on the company’s TAILWIN…

Michelin and Pyrowave Join Forces to Industrialize an Innovative Plastic Waste Recycling Technology

- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology.- They agree to fast track the process industrialization.- The purpose of the technology is to increase the rate of sustain…

TISSIUM Receives FDA Investigational Device Exemption for Vascular Sealant

IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant   TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced toda…

Redx Pharma announces appointment of leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer

Alderley Park, 27 October 2020, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce that it has appointed Dr Jane Robertson as Chief Medical Officer.     Jane is a well respected UK haemato-oncologist with over 17 years' ex…

Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors

October 22, 2020 12:30 AM Eastern Daylight Time   PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal ne…
Show more

Sofinnova Partners Frequently Asked Questions

  • When was Sofinnova Partners founded?

    Sofinnova Partners was founded in 1972.

  • Who are Sofinnova Partners key executives?

    Sofinnova Partners's key executives are Rafaèle Tordjman, Denis Lucquin and Graziano Seghezzi.

  • Where is Sofinnova Partners headquarters?

    Sofinnova Partners headquarters is located at 7 Boulevard Haussmann, Paris.

  • Where are Sofinnova Partners offices?

    Sofinnova Partners has an office in Paris.

  • How many offices does Sofinnova Partners have?

    Sofinnova Partners has 1 office.